Yüklüyor......
PD-L1 expression and prognostic impact in glioblastoma
BACKGROUND: Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequen...
Kaydedildi:
Yayımlandı: | Neuro Oncol |
---|---|
Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
Materyal Türü: | Artigo |
Dil: | Inglês |
Baskı/Yayın Bilgisi: |
Oxford University Press
2016
|
Konular: | |
Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4724183/ https://ncbi.nlm.nih.gov/pubmed/26323609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov172 |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|